Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

IF 1.4 Q3 PERIPHERAL VASCULAR DISEASE Atherosclerosis plus Pub Date : 2023-09-09 DOI:10.1016/j.athplu.2023.09.001
Anastasios Makris , Fotios Barkas , Petros P. Sfikakis , Evangelos Liberopoulos , Theodosios D. Filippatos , Kausik K. Ray , Aris P. Agouridis
{"title":"Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?","authors":"Anastasios Makris ,&nbsp;Fotios Barkas ,&nbsp;Petros P. Sfikakis ,&nbsp;Evangelos Liberopoulos ,&nbsp;Theodosios D. Filippatos ,&nbsp;Kausik K. Ray ,&nbsp;Aris P. Agouridis","doi":"10.1016/j.athplu.2023.09.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><p>Lipoprotein(a) [Lp(a)] and interleuking-6 (IL-6), an inflammation biomarker, have been established as distinct targets of the residual atherosclerotic cardiovascular disease (ASCVD) risk. We aimed to investigate the association between them, and the potential clinical implications in ASCVD prevention.</p></div><div><h3>Methods</h3><p>A literature search was conducted in PubMed until December 31st, 2022, using relevant keywords.</p></div><div><h3>Results</h3><p>Elevated lipoprotein(a) [Lp(a)] levels constitute the most common inherited lipid disorder associated with ASCVD. Although Lp(a) levels are mostly determined genetically by the LPA gene locus, they may be altered by acute conditions of stress and chronic inflammatory diseases. Considering its resemblance with low-density lipoproteins, Lp(a) is involved in atherosclerosis, but it also exerts oxidative, thrombotic, antifibrinolytic and inflammatory properties. The cardiovascular efficacy of therapies lowering Lp(a) by &gt;90% is currently investigated. On the other hand, interleukin (IL)-1b/IL-6 pathway also plays a pivotal role in atherosclerosis and residual ASCVD risk. IL-6 receptor inhibitors [IL-6(R)i] lower Lp(a) by 16–41%, whereas ongoing trials are investigating their potential anti-atherosclerotic effect. The Lp(a)-lowering effect of IL-6(R)i might be attributed to the inhibition of the IL-6 response elements in the promoter region of the LPA gene.</p></div><div><h3>Conclusions</h3><p>Although the effect of IL-6(R)i on Lp(a) levels is inferior to that of available Lp(a)-lowering therapies, the dual effect of the former on both inflammation and apolipoprotein (a) synthesis may prove of equal or even greater significance when it comes ASCVD outcomes. More trials are required to establish IL-6(R)i in ASCVD prevention and elucidate their interplay with Lp(a) as well as its clinical significance.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/ba/main.PMC10500445.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667089523000378","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 1

Abstract

Background and aims

Lipoprotein(a) [Lp(a)] and interleuking-6 (IL-6), an inflammation biomarker, have been established as distinct targets of the residual atherosclerotic cardiovascular disease (ASCVD) risk. We aimed to investigate the association between them, and the potential clinical implications in ASCVD prevention.

Methods

A literature search was conducted in PubMed until December 31st, 2022, using relevant keywords.

Results

Elevated lipoprotein(a) [Lp(a)] levels constitute the most common inherited lipid disorder associated with ASCVD. Although Lp(a) levels are mostly determined genetically by the LPA gene locus, they may be altered by acute conditions of stress and chronic inflammatory diseases. Considering its resemblance with low-density lipoproteins, Lp(a) is involved in atherosclerosis, but it also exerts oxidative, thrombotic, antifibrinolytic and inflammatory properties. The cardiovascular efficacy of therapies lowering Lp(a) by >90% is currently investigated. On the other hand, interleukin (IL)-1b/IL-6 pathway also plays a pivotal role in atherosclerosis and residual ASCVD risk. IL-6 receptor inhibitors [IL-6(R)i] lower Lp(a) by 16–41%, whereas ongoing trials are investigating their potential anti-atherosclerotic effect. The Lp(a)-lowering effect of IL-6(R)i might be attributed to the inhibition of the IL-6 response elements in the promoter region of the LPA gene.

Conclusions

Although the effect of IL-6(R)i on Lp(a) levels is inferior to that of available Lp(a)-lowering therapies, the dual effect of the former on both inflammation and apolipoprotein (a) synthesis may prove of equal or even greater significance when it comes ASCVD outcomes. More trials are required to establish IL-6(R)i in ASCVD prevention and elucidate their interplay with Lp(a) as well as its clinical significance.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脂蛋白(a)、白细胞介素-6抑制剂与动脉粥样硬化性心血管疾病:是否存在关联?
背景和目的脂蛋白(a)[Lp(a)]和白细胞介素-6(IL-6),一种炎症生物标志物,已被确定为残余动脉粥样硬化性心血管疾病(ASCVD)风险的不同靶点。我们旨在研究它们之间的关系,以及在ASCVD预防中的潜在临床意义。方法在PubMed检索相关文献,检索期至2022年12月31日。结果脂蛋白(a)[Lp(a)]水平升高是ASCVD最常见的遗传性脂质紊乱。尽管Lp(a)水平主要由LPA基因座决定,但它们可能会因急性应激和慢性炎症性疾病而改变。考虑到其与低密度脂蛋白的相似性,Lp(a)参与动脉粥样硬化,但它也具有氧化、血栓形成、抗纤溶和炎症特性。将Lp(a)降低>;90%目前正在调查中。另一方面,白细胞介素-1b/IL-6通路在动脉粥样硬化和残余ASCVD风险中也起着关键作用。IL-6受体抑制剂IL-6(R)i]可将Lp(a)降低16-41%,而正在进行的试验正在研究其潜在的抗动脉粥样硬化作用。IL-6(R)i的Lp(a)-降低作用可能归因于LPA基因启动子区中IL-6应答元件的抑制。结论尽管IL-6(R)i对Lp(a)水平的影响不如现有的Lp(a)降低疗法,但前者对炎症和载脂蛋白(a)合成的双重作用可能在ASCVD结果中具有同等甚至更大的意义。需要更多的试验来确定IL-6(R)i在ASCVD预防中的作用,并阐明它们与Lp(a)的相互作用及其临床意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Atherosclerosis plus
Atherosclerosis plus Cardiology and Cardiovascular Medicine
CiteScore
2.60
自引率
0.00%
发文量
0
审稿时长
66 days
期刊最新文献
Adherence to the Healthy Nordic Food Index is associated with reduced plasma levels of inflammatory markers in patients with heterozygous familial hypercholesterolemia A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: Protocol for the EAS Lipid Registry of Africa (LIPRA) Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action? Coronary artery calcification score and 19 biomarkers on cardiovascular events; a 10-year follow-up DanRisk substudy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1